1888 results about "Protein expression" patented technology

The invention provides a multielement polyA polynucleotide for improving mRNA (messenger ribonucleic acid) stability and protein expression and application of the multielement polyA polynucleotide. The invention firstly provides a polynucleotide, the polynucleotide comprises more than two sections of polyA sequence fragments, the adjacent polyA sequence fragments are connected through Linkers, each polyA sequence fragment is composed of one or more continuous A, and each Linker is composed of C and / or G. The polynucleotide provided by the invention can improve mRNA stability and protein expression, and compared with a traditional unit poly-A sequence, the polynucleotide provided by the invention can greatly reduce the recombination rate of fermentation in escherichia coli so as to more easily optimize and amplify the process, and can be better applied to plasmid fermentation related to transcription template preparation in mRNA vaccine or drug production.

The invention provides a protein expression prediction method based on a convolutional neural network and a residual attention mechanism, and belongs to the field of bioinformatics and artificial intelligence. The method comprises the following steps: performing data cleaning and binary one-hot coding on a DNA sequence, inputting the coded DNA sequence into a feature extraction layer, and extracting local features of DNA; local features are extracted through a convolutional neural network, global features are obtained through a multi-head attention mechanism, and residual connection is combined; and finally, inputting the global features into a full connection layer to generate a protein expression prediction result. Furthermore, an SHAP interpretability method is utilized to interpret the output result of the prediction model, and the contribution of the basic group at each position in the DNA sequence to the predicted value is quantified. According to the method, deep learning and interpretability technologies are combined, the precision and credibility of protein expression prediction are remarkably improved, and the method is suitable for predicting protein expression.

The invention discloses a drug resistance prediction method and system based on comparative learning and multi-modal fusion, and the method comprises the steps: firstly generating a molecular map and a molecular fingerprint based on the SMILES of a target drug, and extracting the molecular features of the drug through a comparative learning model constructed through combining a map attention network and a map convolution network; and then, acquiring protein expression, gene expression and metabolic expression data from the target tissue cells, extracting modal features through a deep convolutional network, a Transform encoder and a multi-dimensional attention network, and realizing adaptive fusion of the multi-modal features through a heterogeneous interactive attention mechanism. And finally, jointly inputting the fused multi-modal features and drug molecular features into a multi-layer sensor to realize high-precision prediction of the drug resistance of cells to drugs. By introducing a contrast learning and multi-modal feature fusion mechanism, the characterization capability and prediction precision of the model are effectively improved, and efficient and reliable support can be provided for drug screening and clinical decision making.

The invention belongs to the field of biological medicines, and particularly relates to a varicella-zoster virus gE fusion protein as well as a preparation method and application thereof. The varicella-zoster virus gE fusion protein comprises an amino acid sequence as shown in SEQ ID NO: 1 and at least one of the following fragments: a signal peptide, a Foldon sequence, a Ferritin sequence and a His tag sequence, the signal peptide can improve the protein expression quantity, the Foldon sequence can improve the stability of the protein, the particle size of an antigen can be increased, the immunogenicity of the antigen can be improved, and the fusion protein can be used for preparing a medicine for treating the varicella-zoster virus gE fusion protein. The Ferritin sequence can enhance immune response, a vaccine prepared from the gE fusion protein has excellent immunogenicity, and compared with a commercially available vaccine Shingrix, higher humoral immunity and cellular immunity levels can be induced.

The invention relates to the technical field of protein prediction, and discloses a protein interaction prediction method based on cross-modal enhanced representation learning. According to the method, a Convform module and a Graphform module are designed, and a global attention mechanism is introduced into each module, so that the limitation that only local features or global features are concerned in an existing method is broken through. According to the design, the model can capture the local mode and the global dependency relationship of the protein at the same time, and more comprehensive protein representation is provided. The invention provides a cross-modal enhancement method based on comparative learning. The problem of difference between a sequence mode and a structural mode is solved through an explicit mode alignment process. The method not only can maintain unique information of each mode, but also can give full play to complementarity among the modes, so that richer protein expression is obtained. The cross-protein fusion module provided by the invention can more accurately capture essential characteristics of protein interaction, and the accuracy of PPI prediction is remarkably improved.

The invention provides an UTR (Untranslated Region) element H2202 P1-G as well as a construction method and application thereof, and relates to the technical field of mRNA (messenger ribonucleic acid). According to the present invention, the ribosome load prediction and the secondary structure optimization are performed on the natural 5 'UTR of the HIV TAT 202 gene through the BaidleHelix platform, and the obtained HTAT 202 P1 sequence avoids the inhibitory hairpin structure so as to significantly improve the luciferase expression quantity compared to the natural UTR; an ncRNA sequence without a secondary structure is introduced on the basis of the HTAT 202 P1, translation inhibition of a 5 'cap region is further relieved, and the protein expression quantity of the constructed H2202 P1-G mutant (the DNA sequence of the H2202 P1-G is as shown in SEQ NO 1, and the RNA sequence is as shown in SEQ NO 2) is further improved.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

Relating to the technical field of gene therapy, provided is an siRNA molecule for inhibiting PCSK9 expression, and use thereof. Particularly, an siRNA molecule for inhibiting PCSK9 expression (comprising a sense strand and an anti-sense strand that are complementary to form a double-stranded region) and a pharmaceutical composition comprising the same are disclosed. The siRNA molecule has a high silencing efficiency and a long-lasting silencing effect for PCSK9 gene, and is useful in the manufacture of products for inhibiting PCSK9 protein expression, products for reducing the concentration of low-density lipoprotein or low-density lipoprotein cholesterol in serum; and products for relieving the symptoms of PCSK9 gene-mediated diseases.

The invention discloses application of an ALOX15B gene serving as a target spot to screening of medicines for treating pulmonary vascular remodeling and pulmonary arterial hypertension, and belongs to the technical field of biological medicines. The invention discloses application of an ALOX15B gene or protein expression inhibitor in preparation of a medicine for treating pulmonary vascular remodeling and pulmonary arterial hypertension. By inhibiting expression of the ALOX15B gene or the encoding protein thereof, pulmonary vascular remodeling can be effectively reversed, and rising of pulmonary arterial pressure caused by oxygen deficit can be effectively reversed, so that the ALOX15B gene can be applied to treatment of pulmonary arterial hypertension related diseases.

The present invention relates to a method for constructing an eight-gene-edited xenogeneic organ transplantation donor pig, belonging to the field of animal biotechnology. In the wild-type porcine fetal fibroblast cell line, the GGTA1, β4GalNT2, and CMAH genes are knocked out by using the CRISPR / Cas9 gene editing technology, and the humanized genes of hCD39, hCD46, hCD55, hCD59, and hTBM are transfected. Combining with somatic cell cloning technology, GTKO / β4GalNT2KO / CMAHKO / hCD39 / hCD46 / hCD55 / hCD59 / hTBM eight-gene-edited cloned pigs are constructed. Further, through genotype, mRNA, protein expression identification and functional analysis, eight-gene-edited xenogeneic organ transplantation donor pigs are obtained. The present invention solves the technical problems of high production difficulty, low efficiency, and low survival rate of donor pigs for multi-gene-edited xenogeneic organ transplantation, and maximally solves the common problems of immune rejection reaction and complement dysregulation faced during xenogeneic organ transplantation, laying a foundation for more targeted development of donor pigs suitable for different tissue and organ xenotransplantation, and having important value for promoting the clinical transformation of xenogeneic organ transplantation.

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The invention belongs to the technical field of living cell imaging, and discloses a living cell nucleic acid imaging system and method based on CRISPR (clustered regularly interspaced short palindromic repeats) and a nano antibody and application, the system comprises: a modified dCas protein expression vector containing n antigen polypeptide tags; the modified sgRNA and / or crRNA expression vector comprises a specific guide sequence; the fluorescent nano-antibody expression vector contains m fluorescent nano-antibody coding sequences which are connected in an operable manner, and fluorescent protein serving as an internal tag is inserted between nano-antibody splitting sites, can be combined with a polypeptide tag carried by dCas protein and can stably emit light; and the fluorescent nano antibody in a free state can be self-degraded, so that the fluorescent nano antibody does not emit fluorescence. According to the invention, the single-copy nucleic acid sequence, especially the imaging marker of the single-copy nucleic acid sequence in a living cell, can be visualized with single-molecule resolution and high signal-to-noise ratio.

The invention provides a breast cancer HER2 immunohistochemical digital slice automatic interpretation method, device and equipment and a storage medium. Relates to the technical field of digital pathological image analysis. Acquiring a full-slice image, automatically identifying an external contrast area and a tissue area through a multi-task head real-time instance segmentation model, and segmenting an ROI (Region of Interest) area of tumor cell aggregation; extracting image blocks by adopting a fixed sliding window based on the ROI region, and constructing a double-branch multi-task feature extraction model containing a backbone network: realizing HER2 expression pattern classification by an image block classification head, and outputting a continuous protein expression intensity quantized value by a dyeing intensity numerical head through regression analysis; and establishing a slice-level interpretation model, integrating the classification results and the intensity quantized values of all the image blocks, and outputting an automatic HER2 interpretation result. According to the invention, end-to-end analysis from cell-level characteristic quantification to slice-level diagnosis is realized, and an objective and quantifiable intelligent interpretation scheme is provided for HER2 immunohistochemical evaluation.

The present invention provides a yeast recombinant type XVII humanized collagen and its preparation method, in particular, a recombinant humanized collagen expressing the 15th helical region of type XVII collagen, a recombinant engineering bacterium and its preparation method, belonging to the technical fields of genetic engineering and synthetic biology. The present invention provides the full-length sequence of the 15th helical region of type XVII collagen, and mutants are obtained by mutating amino acid residues based on this sequence; for the first time, the present invention expresses the full-length sequence of the 15th helical region of type XVII collagen in Pichia pastoris, establishes a complete set of fermentation processes and purification processes, improves the protein expression level and reduces degradation, and through experiments, it is verified that the obtained protein has biological activities such as cell adhesion activity and cell migration promotion activity that reach or exceed those of natural human collagen, can achieve the purpose of real product application, and can be widely applied in the fields of medicine, medical devices, biological materials, tissue engineering, cosmetics, etc.

The invention provides a medicine composition for treating cancer. The medicine composition comprises an inhibitor for inhibiting FOXRED2 protein expression and application of Paraprevir in preparation of a medicine for treating cancer. According to the application disclosed by the invention, the new indication of the hepatitis C medicine paritaprevir for inhibiting the malignant process of the liver cancer HCC is found for the first time, the treatment field of the medicine in the liver cancer is expanded, and a theoretical basis is provided for developing a new target spot for treating the liver cancer.

The present disclosure relates to the seminal discovery of a generation and use of genetically engineered Vibrio sp. Provided is the use of the genetically engineered bacteria for the construction, maintenance, manipulation, and / or propagation of DNA constructs; protein expression; protein secretion; vectors and other metabolic tools; metabolic engineering; expression of cellular extracts for cell-free biology; shuttle vectors; cloning vectors; and for synthetic biology applications. The disclosure also relates to the use of the replication machinery of Vibrio sp. as a cloning or expression vector for replication of recombinant DNA constructs. The disclosure also relates to methods of use of the above.

The invention relates to application of 12-ketolithocholic acid in preparation of a medicine for preventing or treating acute ischemic intestinal injury. According to the application, 12-ketolithocholic acid (12-KLCA) is used for preventing or treating acute ischemic intestinal injury and is verified on a constructed classical intestinal ischemia reperfusion model, and a verification result shows that the 12-KLCA obviously improves intestinal histopathologic injury induced by intestinal ischemia reperfusion of a mouse, improves the survival rate of the mouse, and has a good application prospect in prevention or treatment of acute ischemic intestinal injury. The protein expression level of the apoptosis factor activated caspase-3 is reduced, the effect is obvious, safety and non-toxicity are achieved, and the side effect is small.

The invention provides a rapid quantitative analysis method for an outer vesicle proteome, and belongs to the technical field of quantitative analysis of the outer vesicle proteome. According to the rapid quantitative analysis method for the outer vesicle proteome, firstly, a high-quality outer vesicle sample is obtained through low-speed centrifugation, ultra-speed centrifugation and membrane filtration; and obtaining proteome data by utilizing two-dimensional electrophoresis and mass spectrometry. Then, a mathematical model equation set is constructed for preliminary analysis, a protein interaction network is optimized through an embedded game optimization index model, and feature extraction and quantitative analysis are conducted through a convolution parameter adaptive function and a residual network deep learning model; finally, a quantitative analysis result containing the protein expression level and the function importance is generated in combination with the multi-dimensional protein expression contribution index, and the technical problem that in the prior art, in the rapid quantitative analysis process of the outer vesicle proteome, the protein component complexity is high, and consequently the quantitative precision is low is solved.

The invention belongs to the technical field of environmental biology, and particularly relates to a prothioconazole methyltransferase gene proS38 and application thereof. The prothioconazole methyltransferase proS38 gene in the Sphingomonas sp.AJ-1 strain and the prothioconazole methyltransferase which is a protein expression substance thereof are found through analysis, screening, identification and verification, the prothioconazole methyltransferase proS38 gene and the prothioconazole methyltransferase which is a protein expression substance thereof are proved to have efficient and specific degradation catalysis capability on the existing pesticide prothioconazole which is used in a large amount, and a foundation is laid for biodegradation of prothioconazole.

The invention belongs to the technical field of functional nanoprobes and biological detection, and particularly relates to a kit for simultaneously detecting a specific membrane protein marker and a membrane protein dimer and application of the kit. The detection kit comprises a membrane proteome anchoring chain, a recognition probe, an SERS probe and an auxiliary signal amplification reagent, by combining DNA logic sensing based on aptamer recognition and logic response type assembly based on EpCAM protein expression and DNA signal amplification of Met protein dimerization, networked assembly of a recognition probe and an SERS probe is realized, so that specific accurate recognition of tumor cells and high-sensitivity SERS detection and imaging of membrane protein dimers are realized; the method is suitable for monitoring an HGF / Met signal channel based on Met protein dimerization mediation between stromal cells and cancer cells in a complex tumor microenvironment, and can evaluate the inhibition effect of a targeted drug on receptor dimerization in real time.

The invention relates to a method for inhibiting in-vitro infection of a porcine epidemic diarrhea virus by using JPH203 and application. The JPH203 can be used for preparing an antiviral drug for inhibiting infection of the porcine epidemic diarrhea virus. JPH203 with the concentration of 5 [mu] M is added in the process that Vero cells are infected with PEDV, compared with a control group without JPH203, the virus infection condition, the protein expression quantity, the RNA content and the virus titer of the PEDV in a treatment group with JPH203 are all remarkably reduced, and it is indicated that JPH203 can be used for inhibiting in-vitro infection of the porcine epidemic diarrhea virus.

The present invention provides a self-activating small molecule induction system, cells, and applications and methods in inducing gene expression, belonging to the technical field of genetic engineering. The self-activating small molecule induction system optimizes the component composition based on the green light response system, improves the induction efficiency of the target gene through a cascade reaction, and can reduce the background leakage level, playing an important role in the induction of the target gene and having good application prospects in the field of protein expression and the production and preparation of viral vectors.

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

To provide a nucleic acid having reduced cytotoxic activity and enhanced protein production, a pharmaceutical composition comprising the nucleic acid, and a method of producing the nucleic acid.SOLUTION: Provided are: a nucleic acid including a protein-encoding region that has been modified, wherein the total proportion of uracil residues and adenine residues in the modified protein-encoding region is reduced in comparison to that in the protein-encoding region prior to modification; and a method of producing the nucleic acid.SELECTED DRAWING: None

A fusion protein comprising at least one first polypeptide moiety and at least one second polypeptide moiety, wherein the first polypeptide moiety is a single-chain polypeptide capable of binding a target entity, and the second polypeptide moiety is a stabilizing polypeptide and comprises a single-chain α-helix-containing domain, wherein the second polypeptide moiety does not have binding affinity for said target entity. The presence of the second polypeptide moiety can improve at least one property of the fusion protein as compared to the property of the first polypeptide moiety alone, wherein said improved property is selected from the group consisting of: alkaline stability, recombinant protein expression and coupling to a support.

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

The invention provides application of an Aars1 gene in regulation and control of expression of an exogenous recombinant protein, and belongs to the technical fields of recombinant protein expression, gene engineering and cell culture. According to the CHO cell line, shRNA fragments of targeted Aars1 genes are inserted and integrated into piggyBac transposon vectors, a recombinant vector for inhibiting / silencing the Aars1 genes and an Aars1 low-expression CHO cell line are constructed, the CHO cell line can remarkably reduce the mRNA expression level of the Aars1, meanwhile, the CHO cell line serves as a host cell for recombinant protein expression, and compared with a wild type CHO cell line, the CHO cell line has the advantages that the expression level of the CHO cell line is greatly improved; the recombinant adalimumab can improve the expression quantity of recombinant protein (the expression quantity of the recombinant adalimumab is increased by 3.1 + / -0.18 times), effectively overcomes the problem of low expression level of the existing CHO cell expression system, and can be used for further constructing a recombinant protein expression system or kit.

The invention belongs to the technical field of protein mixing, and particularly relates to a mixing device for producing drawing protein and a mixing method thereof.The mixing device comprises a shell assembly, a stirring assembly is arranged in the shell assembly, and a plurality of mixing assemblies are evenly arranged in the stirring assembly; the shell assembly comprises a shell, and a mixing cavity is formed in the shell; the stirring assembly comprises a rotating cylinder, an inner groove is formed in one side of the rotating cylinder, a liquid inlet pipe is arranged in the inner groove, and a plurality of vertical rods are uniformly arranged on the outer surface of the rotating cylinder; the mixing assembly comprises a fixed frame, a movable groove is formed in one side of the fixed frame, and an elastic movable plate is movably connected to the interior of the movable groove in a sealed mode; the mixing device is high in mixing efficiency, good in mixing effect, higher in adaptability, higher in stability, simpler to operate and suitable for large-scale production operation, meets the requirement for efficient production of the drawing protein, and ensures the component quality of the subsequent drawing protein.

The invention provides a method and a device for designing a protein coding codon sequence based on a large multi-modal model, which comprehensively utilize information such as an amino acid sequence, space folding and mRNA quality of protein to realize high-quality, controllable and evaluable codon sequence design. According to the method, the dependence of a traditional codon optimization strategy on a reference gene template is broken through, and a codon optimization problem is converted into a codon design task based on protein information. Through comprehensive consideration of information such as space folding of protein, context of amino acid sequences, mRNA quality and the like, the model can generate a codon sequence which is more in line with codon use preference of specific species, reasonable in structure and efficient in expression, so that a new thought and technical support are provided for safe, stable, efficient and controllable protein expression.

The invention relates to the technical field of biotechnology and gene function and application, and provides application of SNHG8 in preparation of drugs for preventing and treating non-alcoholic fatty liver diseases. The medicine is used for preventing and treating the non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The SNHG8 is applied to preparation of the medicine for preventing and treating the non-alcoholic fatty liver disease, the medicine can effectively reduce the content of triglyceride in the liver by promoting SNHG8 gene expression, liver lipid accumulation increase and lipid metabolism related protein expression up-regulation induced by high-fat and high-cholesterol diet are relieved, and therefore the non-alcoholic fatty liver disease is prevented, treated or relieved. The purpose of preventing and treating the non-alcoholic fatty liver disease is achieved.